A Comparison of the Effect of Decorsin and Two Disintegrins, Albolabrin and Eristostatin, on Platelet Function^[*]

Summary

Naturally-occurring fibrinogen receptor antagonists and platelet aggregation inhibitors that are found in snake venom (disintegrins) and leeches share many common features, including an RGD sequence, high cysteine content, and low molecular weight. There are, however, significant selectivity and potency differences. We compared the effect of three proteins on platelet function: albolabrin, a 7.5 kDa disintegrin, eristostatin, a 5.4 kDa disintegrin in which part of the disintegrin domain is deleted, and decorsin, a 4.5 kDa non-disintegrin derived from the leech Macrobdella decora, which has very little sequence similarity with either disintegrin. Decorsin was about two times less potent than albolabrin and six times less potent than eristostatin in inhibiting ADP- induced human platelet aggregation. It had a different pattern of interaction with glycoprotein IIb/IIIa as compared to the two disintegrins. Decorsin bound with a low affinity to resting platelets (409 nM) and to ADP-activated platelets (270 nM), and with high affinity to thrombin- activated platelets (74 nM). At concentrations up to 685 nM, it did not cause expression of a ligand-induced binding site epitope on the (β₃ subunit of the GPIIb/IIIa complex. It did not significantly inhibit isolated GPIIb/IIIa binding to immobilized von Willebrand Factor. At low doses (1.5-3.0 μg/mouse), decorsin protected mice against death from pulmonary thromboembolism, showing an effect similar to eristostatin. This suggested that decorsin is a much more potent inhibitor of platelet aggregation in vivo than in vitro, and it may have potential as an antiplatelet drug.

^*This investigation was supported by NIH grants HL 45486 (SN), and K0702658 (AKR), a predoctoral fellowship (MAM) and Grant-in-Aid (AKR) from the American Heart Association, Southeastern Pennsylvania Chapter, a post-doctoral traineeship grant T32HL07777 (MAM), a fellowship from the European Economic Community, Regione Abruzzo (LB), and grants from the Italian Association for Cancer Research (LB) and the American-Italian Foundation for Cancer Research 94-102 (LB).

• References

• 1 Niewiarowski S, McLane MA, Kloczewiak M, Stewart GJ. Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors. Sem Hematol 1994; 31: 289-300
• 2 Lazarus RA, McDowell RS. Structural and functional aspects of RGD containing protein antagonists of glycoprotein Ilb-IIIa. Curr Opin Biotechnol 1993; 4: 438-445
• 3 McLane MA, Kowalska MA, Silver L, Shattil SJ, Niewiarowski S. Interaction of disintegrins with the alllb(3₃receptor on resting and activated platelets. Biochem J 1994; 301: 429-436
• 4 Pfaff M, McLane MA, Beviglia L, Niewiarowski S, Timpl R. Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins αIIIbβ₃, α_v(β₃and α₅β₁and in cell adhesion inhibition. Cell Adhes Comm. 1994 (in press)
• 5 Lasz EC, McLane MA, Trybulec M, Kowalska MA, Khan S, Budzynski AZ, Niewiarowski S. β₃integrin derived peptide 217-230 inhibits fibrinogen binding and platelet aggregation: Significance of RGD sequences and fibrinogenAα-chain. Biochem Biophys Res Comm 1993; 190: 118-124
• 6 Krezel AM, Wagner G, Seymour-Ulmer J, Lazarus R. Structure of the RGD protein decorsin: Conserved motif and distinct function in leech proteins that affect blood clotting. Science 1994; 264: 1944-1947
• 7 Cook JJ, Trybulec M, Lasz EC, Khan S, Niewiarowski S. Binding of glycoprotein Ilia-derived peptide 217-231 to fibrinogen and von Willebrand factor and its inhibition by platelet glycoprotein Ilb/IIIa complex. Biochim Biophys Acta 1992; 1119: 312-321
• 8 Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204
• 9 Shattil JJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-315
• 10 Williams J, Rucinski B, Holt J, Niewiarowski S. Elegantin and albolabrin purified peptides from viper venoms: Homologies with the RGDS domain of fibrinogen and von Willebrand factor. Biochem Biophys Acta 1990; 1039: 81-89
• 11 Niewiarowski S, Budzynski AZ, Morinelli TA, Brudzynski TM, Stewart GJ. Exposure of fibrinogen receptor on human platelets by proteolytic enzymes. J Biol Chem 1981; 256: 917-925
• 12 Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-672
• 13 O’Toole TE, Loftus JC, Du X, Glass AA, Ruggeri ZM, Shattil SJ, Plow EF, Ginsberg MH. Affinity modulation of the alllb(3₃integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor. Cell Reg 1990; 1: 883-893
• 14 Coller BS. A new murine monoclonal antibody reports on activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein Ilb/IIIa complex. J Clin Invest 1985; 76: 101-108
• 15 Beviglia L, Poggi A, Rossi C, McLane MA, Calabrese R, Cook JJ, Niewiarowski S. Mouse antithrombotic assay. Inhibition of platelet thromboembolism by disintegrins. Thromb Res 1993; 71: 301-315
• 16 Altman D. Comparing Groups-Categorical Data. In: Practical Statistics for Medical Research. New York, NY: Chapman & Hall: 1991. pp 253-257
• 17 Frelinger AL, Du X, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin αIIb(β₃(glycoprotein IIb-IIIa) alter affinity, specificity and function. J Biol Chem 1991; 266: 17106-17111
• 18 Kouns WC, Weller T, Hadvary P, Jennings LK, Steiner B. Identification of a peptidomimetic inhibitor with minimal effects on the conformation of GPIIb-IIIa. Blood 1992; 80: 165a abstr 650
• 19 Adler M, Carter P, Lazarus RA, Wagner G. Cysteine pairing in the glycoprotein Ilb-IIIa antagonist kistrin using NMR, chemical analysis, and structure calculations. Biochem 1993; 32: 282-289
• 20 Saudek V, Atkinson RA, Pelton JT. Three dimensional structure of echista- tin, the smallest active RGD protein. Biochem 1991; 30: 7369-7372
• 21 Senn H, Klaus W. The nuclear magnetic resonance solution structure of flavoridin, an antagonist of the platelet GPIIb-IIIa receptor. J Mol Biol 1993; 232: 907-925
• 22 Takeya H, Oda K, Omori-Satoh T, Iwanaga S. The complete amino acid sequence of the high molecular mass hemorrhagic protein HR lb isolated from the venom of Trimeresurus flavoridis. J Biol Chem 1990; 265: 16068-16073
• 23 Huang T-F, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin: A low molecular weight peptide inhibiting fibrinogen interaction with platelet expressed glycoprotein IIb-IIIa complex. J Biol Chem 1987; 262: 16157-16163
• 24 Houdijk WP M, Sakariassen K, Nievelstein P, Sixma JJ. Role of factor VIII- von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar collagen types I and III. J Clin Invest 1985; 75: 531-540
• 25 Beacham DA, Wise RJ, Turci SM, Handin RI. Selective inactivation of the Arg-Gly-Asp-Ser (RGDS) binding site in vWf by site-directed mutagenesis. J Biol Chem 1992; 267: 3409-3415
• 26 Juliano D, Wang Y, Kowalska MA, Stewart GJ, Niewiarowski S. Characterization of α_vβ₃receptor on human umbilical vein endothelial cells (HUVEC) by disintegrins and monoclonal antibodies. FASEB J. 1995 9. A3587